Manuela Helmer-Citterich
professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Preeclampsia is a life-threatening pregnancy disorder with significant maternal and neonatal implications, and few diagnostic and therapeutic strategies. In this study, we integrated six placental transcriptomic datasets to identify a robust preeclampsia-specific gene signature, which revealed key dysregulated processes, including hypoxia, immune dysfunction, and metabolic disruption. We applied Multivariate INTegrative (MINT) integration to derive a smaller, predictive gene signature optimized for biomarker discovery. Validation in a longitudinal blood dataset demonstrated its potential as blood-based biomarkers for early diagnosis and monitoring. Using the meta-analysis signature, we conducted a drug repurposing analysis that identified 63 candidate therapeutics for preeclampsia. Lansoprazole, a widely available proton pump inhibitor with a favorable safety profile, emerged as the top candidate. Preclinical evaluation using a mouse preeclampsia model triggered by partial depletion of maternal FOXP3+ regulatory CD4 T cells showed lansoprazole treatment overrides normally increased soluble FLT1 levels with protection against fetal wastage. Together integrating computational and experimental approaches lays the foundation for further investigating lansoprazole as a therapeutic candidate for preeclampsia.
Year:
2026
Transcription factors (TFs) are key regulators of cellular gene expression programs in health and disease. Here we set out to integrate genomic, transcriptomic, and phosphoproteomic data to characterize TF activity in lung adenocarcinoma patients. Using expression data from patient samples and genomic information on TF binding to super-enhancers, starting from a list of 1667 human TFs we calculated a patient-specific activity score and identified 34 with perturbed activity in the cancer samples, as evidenced by the expression of their direct targets. We then leveraged phosphoproteomic data on the same samples to identify phosphorylation events that modulate TF activity. This novel data integration approach to TF characterization led to the identification of ERG as a key regulator in lung adenocarcinoma whose activity strongly correlates with patient survival.
Year:
2025
Cardiovascular diseases (CVDs) represent a major concern for global health whose mechanistic understanding is complicated by a complex interplay between genetic predisposition and environmental factors. Specifically, heart failure (HF), encompassing dilated cardiomyopathy (DC), ischemic cardiomyopathy (ICM), and hypertrophic cardiomyopathy (HCM), is a topic of substantial interest in basic and clinical research. Here we used a Partial Correlation Coefficient-based algorithm (PCC) within the context of a meta-analysis framework, to construct a Gene Regulatory Network (GRN) that identifies key regulators whose activity is perturbed in Heart Failure. By integrating data from multiple independent studies, our approach unveiled crucial regulatory associations between transcription factors (TFs) and structural genes, emphasizing their pivotal roles in regulating metabolic pathways, such as fatty acid metabolism, oxidative stress response, epithelial-to-mesenchymal transition, and coagulation. In addition to known associations, our analysis also identified novel regulators, including the identification of TFs FPM315 and MOVO-B, which are implicated in dilated cardiomyopathies, and TEAD1 and TEAD2 in both dilated and ischemic cardiomyopathies. Moreover, we uncovered alterations in adipogenesis and oxidative phosphorylation pathways in hypertrophic cardiomyopathy, and discovered a role for IL2 STAT5 signaling in heart failure. Our findings underscore the importance of TFs activity in the initiation and progression of cardiac disease, highlighting their potential as pharmacological targets.
Year:
2024
Currently, the identification of patient-specific therapies in cancer is mainly informed by personalized genomic analysis. In the setting of acute myeloid leukemia (AML), patient-drug treatment matching fails in a subset of patients harboring atypical internal tandem duplications (ITDs) in the tyrosine kinase domain of the FLT3 gene. To address this unmet medical need, here we develop a systems-based strategy that integrates multiparametric analysis of crucial signaling pathways, patient-specific genomic and transcriptomic data with a prior-knowledge signaling network using a Boolean-based formalism. By this approach, we derive personalized predictive models describing the signaling landscape of AML FLT3-ITD positive cell lines and patients. These models enable us to derive mechanistic insight into drug resistance mechanisms and suggest novel opportunities for combinatorial treatments. Interestingly, our analysis reveals that the JNK kinase pathway plays a crucial role in the tyrosine kinase inhibitor response of FLT3-ITD cells through cell cycle regulation. Finally, our work shows that patient-specific logic models have the potential to inform precision medicine approaches.
Year:
2024
Collaborators (4)
Brice Gaudilliere
Associate Professor
Stanford University
tomiko oskotsky
University of California, San Francisco
Patrizia Chiusolo
Università Cattolica del Sacro Cuore
Francesca Sacco
Associate Professor of Genetics
University of Rome Tor Vergata
Make your next move.
Prepare your application
Review drafts before you send them.